USPTO Examiner GRASER JENNIFER E - Art Unit 1645

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18944516BACILLUS STRAINS FOR IMPROVING FEED CONVERSION RATES AND BODY WEIGHT GAIN IN ANIMALSNovember 2024June 2025Allow710NoNo
18787340LIVE TESTS FOR DIAGNOSIS OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY IN ANIMALS AND HUMANSJuly 2024April 2025Allow811YesNo
18763332MITIGATION OF CRYPTOSPORIDIOSIS USING HYDROGEN PEROXIDE-GENERATING COMPOSITIONSJuly 2024March 2025Allow800NoNo
18741232PURIFIED CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAEJune 2024June 2025Allow1210NoNo
18734806OMPG VARIANTSJune 2024June 2025Allow1200YesNo
18665018MULTIVALENT OSPA POLYPEPTIDES AND METHODS AND USES RELATING THERETOMay 2024February 2025Allow900NoNo
18662515MICROBIOME RELATED IMMUNOTHERAPIESMay 2024March 2025Allow1010NoNo
18660419IMMUNOGENIC COMPOSITIONS AND USES THEREOFMay 2024June 2025Allow1310NoNo
18637589METHODS FOR PRODUCING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CARRIER PROTEIN CONJUGATESApril 2024May 2025Allow1320NoNo
18633691LONG LASTING EFFECT OF NEW BOTULINUM TOXIN FORMULATIONSApril 2024April 2025Allow1210NoNo
18599359ANTIBODIES AGAINST MICROORGANISMS AND USES THEREOFMarch 2024June 2025Abandon1601NoNo
18442506CATTLE FEVER TICK-INFESTATION VACCINES AND USES THEREOFFebruary 2024February 2025Allow1210NoNo
18440212MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDESFebruary 2024May 2025Allow1510NoNo
18424354SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOFJanuary 2024May 2025Allow1511NoNo
18409857GUT MICROBES AGAINST INFECTIOUS DISEASES AND ITS USEJanuary 2024February 2025Allow1311NoNo
18544698SLAM POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOFDecember 2023January 2025Allow1310YesNo
18533453PROBIOTIC BACTERIAL STRAINS PRODUCING ANTIMICROBIAL PROTEINS AND COMPOSITIONS COMPRISING THESE FOR USE IN THE TREATMENT OF DIARRHEAL AND OTHER MICROBIAL DISEASESDecember 2023January 2025Abandon1301NoNo
18532731INFECTIOUS PLASMODIUM SPOROZOITES GROWN IN VITRODecember 2023August 2024Allow810NoNo
18501825ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTANovember 2023October 2024Allow1122NoNo
18493396Bacteriophage Composition And Method of Preventing Bacterial Infections in LivestockOctober 2023November 2024Allow1310NoNo
18487437COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND ANOTHER BIOLOGICAL CONTROL AGENTOctober 2023November 2024Allow1311NoNo
18378736SYSTEM, METHOD, APPARATUS AND DIAGNOSTIC TEST FOR PLASMODIUM VIVAXOctober 2023December 2024Allow1510NoNo
18485268BACILLUS STRAINS FOR IMPROVING FEED CONVERSION RATES AND BODY WEIGHT GAIN IN ANIMALSOctober 2023August 2024Allow1010NoNo
18464051ANTIGENS FOR DETECTING TOXOPLASMA INFECTION BY MONITORING CELLULAR IMMUNITYSeptember 2023August 2024Allow1110NoNo
18451461COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERIAugust 2023June 2024Allow1020YesNo
18449904OMPG VARIANTSAugust 2023March 2024Allow700NoNo
18350267BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOFJuly 2023March 2025Allow2120NoNo
18344780IMMUNOGENICITY OF A CPG-ADJUVANTED RECOMBINANT PLAGUE VACCINEJune 2023March 2025Allow2111YesNo
18343944MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF FIBROSISJune 2023December 2023Allow500YesNo
18338961GLYCOCONJUGATION PROCESSES AND COMPOSITIONSJune 2023December 2024Allow1810NoNo
18335489ANTI-LAM AND ANTI-PIM6/LAM MONOCLONAL ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONSJune 2023February 2025Allow2010NoNo
18335717GENETICALLY MODIFIED HAPLOID ISSATCHENKIA ORIENTALISJune 2023September 2024Allow1520NoNo
18331298Combinations of Yersinia Entomophaga and Pesticides or Other SubstancesJune 2023April 2024Allow1110NoNo
18203917PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING PASTEURELLA PROTEINS AND METHODS OF USEMay 2023October 2024Allow1721NoNo
18318909SOUTHERN CATTLE TICK VACCINE PRODUCTMay 2023April 2024Allow1120NoNo
18316499Attenuating bacterial virulence by attenuating bacterial folate transportMay 2023February 2024Allow900NoNo
18144568POLYPEPTIDES OF FUSOBACTERIUM AND METHODS OF USEMay 2023August 2024Allow1521NoNo
18309555COMPOSITIONS FOR USE AS A PROPHYLACTIC AGENT TO THOSE AT RISK OF INFECTION OF TUBERCULOSIS, OR AS SECONDARY AGENTS FOR TREATING INFECTED TUBERCULOSIS PATIENTSApril 2023July 2024Abandon1510NoNo
18188969COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOFMarch 2023February 2024Allow1000NoNo
18188987COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOFMarch 2023August 2024Abandon1710NoNo
18026904MICROORGANISM STRAIN PEDIOCOCCUS ACIDILACTICI TAK 589 COCCOBEST AS AN ANTIMICROBIAL AND ANTIOXIDANT PROBIOTICMarch 2023June 2025Allow2700NoNo
18159718MUTANT PORESJanuary 2023October 2024Allow2010NoNo
18155301LONG LASTING EFFECT OF NEW BOTULINUM TOXIN FORMULATIONSJanuary 2023December 2023Allow1110YesNo
18154642VACCINE FOR FALCIPARUM MALARIAJanuary 2023August 2024Allow2020NoNo
18088690BURKHOLDERIA PSEUDOMALLEI COMPLEX OUTER MEMBRANE VESICLES AS ADJUVANTSDecember 2022October 2023Allow1020NoNo
18145411METHOD OF PRODUCING STREPTOCOCCUS THERMOPHILUS MUTANT STRAINSDecember 2022March 2023Allow300NoNo
18062934MICROBIOTA RESTORATION THERAPY (MRT), COMPOSITION AND METHODS OF MANUFACTUREDecember 2022January 2024Allow1410YesNo
18060401TETANUS VACCINE PLATFORM FOR EMBEDDING COVID-19 VACCINENovember 2022September 2024Allow2131YesNo
17923853SHIGELLA-BASED MINIMAL PLASMID RECOMBINANT INVASION CONSTRUCTNovember 2022April 2025Allow2900NoNo
18052434CHIMERIC M. HYORHINIS POLYPROTEIN FOR VACCINES AND DIAGNOSTICSNovember 2022September 2023Allow1120NoNo
18052038CATTLE FEVER TICK-INFESTATION VACCINES AND USES THEREOFNovember 2022November 2023Allow1211YesNo
18049507METHODS FOR PRODUCING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CARRIER PROTEIN CONJUGATESOctober 2022January 2024Allow1521NoNo
18047395MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONSOctober 2022May 2024Allow1920NoNo
17938184Synergistic Bacterial Compositions and Methods of Production and Use ThereofOctober 2022April 2024Allow1911NoNo
17953712MALARIA IMMUNOGEN AND METHODS FOR USING SAMESeptember 2022June 2024Allow2121YesNo
17933952Method for Diagnostics, Treatment and Prevention of Parkinson's DiseaseSeptember 2022October 2023Allow1310YesNo
17933516COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSESSeptember 2022March 2023Allow601NoNo
17933582MANAGEMENT OF PATHOGENIC LAWSONIASeptember 2022July 2023Allow1010NoNo
17888916POLYPEPTIDES OF FUSOBACTERIUM AND METHODS OF USEAugust 2022August 2024Allow2421YesNo
17885784IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOFAugust 2022February 2023Allow700NoNo
17885446PROBIOTIC FORMULATIONS AND METHODS FOR USEAugust 2022January 2025Abandon2920NoNo
17817113PROTISTS ENRICHED WITH LIPIDS RICH IN POLYUNSATURATED FATTY ACIDSAugust 2022September 2024Allow2511NoNo
17817272BORDETELLA STRAINS EXPRESSING SEROTYPE 3 FIMBRIAEAugust 2022May 2025Allow3310NoNo
17814281STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND CONJUGATES THEREOFJuly 2022February 2025Allow3100NoNo
17813065COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND ANOTHER BIOLOGICAL CONTROL AGENTJuly 2022June 2023Allow1101YesNo
17852211Animal Protein-Free Pharmaceutical CompositionsJune 2022October 2022Allow420YesNo
17808678COMPOSITION COMPRISING NEW LACTOBACILLUS SALIVARIUS STRAINS AND METHOD FOR THE PREVENTION AND TREATMENT OF OTITIS AND UPPER RESPIRATORY INFECTIONSJune 2022November 2023Allow1620NoNo
17829033VIRULENT AEROMONAS VACCINES AND METHODSMay 2022January 2024Abandon1910NoNo
17826617VACCINES AGAINST MALARIA TRANSMISSIONMay 2022June 2023Allow1312YesNo
17824378COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA OR LIMITING EIMERIA INFECTIONMay 2022October 2023Allow1711NoNo
17752277METHOD AND A SOLID SUPPORT FOR DETECTING TICK-BORNE MICROBES IN A BIOLOGICAL SAMPLEMay 2022January 2023Allow800YesNo
17742023ANTIGENS FOR DETECTING TOXOPLASMA INFECTION BY MONITORING CELLULAR IMMUNITYMay 2022November 2023Abandon1811NoNo
17728483ANTI HLA-G SPECIFIC ANTIBODIESApril 2022December 2022Allow711NoNo
17723123ACETIC ACID BACTERIA-CONTAINING COMPOSITIONApril 2022June 2025Allow3811NoNo
17659466Compositions and methods for treating and preventing staphylococcus aureus infectionsApril 2022May 2023Allow1310NoNo
17719674MITIGATION OF CRYPTOSPORIDIOSIS USING HYDROGEN PEROXIDE-GENERATING COMPOSITIONSApril 2022April 2024Allow2411NoNo
17714205Probiotic Immunomodulatory CompositionsApril 2022March 2023Allow1110NoNo
17705461COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERIMarch 2022May 2023Allow1410NoNo
17764371THE COMPOSITION OF CULTURE MEDIA FOR FAECALIBACTERIUM PRAUSNITZIIMarch 2022February 2025Allow3510NoNo
17698645OPTIMIZED CROSSLINKERS FOR TRAPPING A TARGET ON A SUBSTRATEMarch 2022April 2024Allow2510NoNo
17638528STRAIN HAVING ABILITY TO LOWER BLOOD AMMONIA LEVELS AND COMPOSITION COMPRISING SAME FOR NEURONAL PROTECTIONMarch 2022February 2025Allow3611NoNo
17687313MODIFIED BRUCELLA VACCINE STRAIN FOR THE TREATMENT OF BRUCELLOSISMarch 2022March 2023Allow1210NoNo
17684018BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOFMarch 2022May 2023Allow1401NoNo
17679243COMPOSITIONS COMPRISING OF BACTERIAL STRAINSFebruary 2022May 2023Abandon1510NoNo
17651523NOVEL ANTI-LAM AND ANTI-PIM6/LAM MONOCLONAL ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONSFebruary 2022March 2023Allow1220NoNo
17633105COMPOSITIONS AND METHODS OF TREATING PSORIASIS AND ATOPIC DERMATITIS USING PREVOTELLA HISTICOLAFebruary 2022January 2025Abandon3510NoNo
17588760METHODS OF USING MONOCLONAL ANTIBODIES TARGETING EPITOPES OF ASPHJanuary 2022June 2023Abandon1610NoNo
17586968COMPOSITIONS COMPRISING BACTERIAL STRAINSJanuary 2022January 2023Abandon1110NoNo
17588122SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOFJanuary 2022October 2023Allow2111NoNo
17628640MALARIA IMMUNOGEN AND METHODS FOR USING SAMEJanuary 2022July 2024Allow3000YesNo
17578537Application of breast milk-derived Lactobacillus reuteri in regulating maternal and infant immune functionJanuary 2022September 2024Allow3210NoNo
17626628COMPOSITION AND METHOD FOR PREVENTING, ALLEVIATING, OR TREATING LIVER INJURYJanuary 2022February 2025Allow3721NoNo
17625715ANTIBODY COMPOSITIONS FOR DISRUPTING BIOFILMSJanuary 2022September 2024Allow3201NoNo
17622546OLFACTORY RECEPTOR AS MICROGLIA MARKER AND USE THEREOFDecember 2021January 2025Allow3711YesNo
17556294METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING AUTOIMMUNE DISEASESDecember 2021May 2025Allow4121NoNo
17596652ANTIBODY-MEDIATED NEUTRALIZATION OF BETA-LACTAMASESDecember 2021April 2025Allow4011NoNo
17644019VACCINESDecember 2021December 2023Allow2411NoNo
17618582PROBIOTIC AND CHEMICAL CONTROL OF BIOFILMSDecember 2021December 2024Abandon3601NoNo
17549845METHODS OF PRODUCING AGGREGATE-FREE MONOMERIC DIPHTHERIA TOXIN FUSION PROTEINS AND THERAPEUTIC USESDecember 2021December 2023Allow2411NoNo
17617802DETECTION OF ANTIGENSDecember 2021March 2025Allow3911YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GRASER, JENNIFER E.

Strategic Value of Filing an Appeal

Total Appeal Filings
52
Allowed After Appeal Filing
15
(28.8%)
Not Allowed After Appeal Filing
37
(71.2%)
Filing Benefit Percentile
40.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 28.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GRASER, JENNIFER E - Prosecution Strategy Guide

Executive Summary

Examiner GRASER, JENNIFER E works in Art Unit 1645 and has examined 1,313 patent applications in our dataset. With an allowance rate of 73.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.

Allowance Patterns

Examiner GRASER, JENNIFER E's allowance rate of 73.2% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by GRASER, JENNIFER E receive 1.51 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GRASER, JENNIFER E is 25 months. This places the examiner in the 65% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +27.0% benefit to allowance rate for applications examined by GRASER, JENNIFER E. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 35.5% of applications are subsequently allowed. This success rate is in the 75% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 57.1% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 86.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 75.7% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 12.1% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.6% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.